Molecular Stratification of Chronic Kidney Disease
Anna Reznichenko(AstraZeneca (Sweden)), Matthias Kretzler(University of Michigan), Julie M. Williams(Queen Elizabeth Hospital Birmingham), Carol Moreno Quinn(AstraZeneca (United Kingdom)), Shawn S. Badal(Gilead Sciences (United States)), Timothy Slidel(AstraZeneca (United Kingdom)), Markus Bitzer(Oregon Health & Science University), Mark Tomilo(University of Michigan), Sven Moosmang(Boehringer Ingelheim (Germany)), Matthew D. Breyer(Johnson & Johnson (United States)), Maria Chiara Magnone(Janssen (Belgium)), James Conway(AstraZeneca (United States)), Johnna D. Wesley(Novo Nordisk (United States)), Wenjun Ju(Xuzhou Medical College), Ratan V. Bhat(AstraZeneca (Sweden)), Uptal D. Patel(Medical University of Vienna), Anil Karihaloo(Novo Nordisk (United States)), John T. Liles(Gilead Sciences (United States)), Sean Eddy(University of Michigan), Kevin L. Duffin(Eli Lilly (United States)), Viji Nair(University of Michigan)
Cited by 2
Related Papers
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
|Kidney International|2020|724
Role of Hippocampal Ca<sub>v</sub>1.2 Ca<sup>2+</sup>Channels in NMDA Receptor-Independent Synaptic Plasticity and Spatial Memory
|Journal of Neuroscience|2005|428